January 10, 2017 / 12:20 PM / 7 months ago

BRIEF-U.S. FDA clears Pluristem's Phase III study of PLX-PAD cells for treatment of critical limb ischemia

Jan 10 (Reuters) - Pluristem Therapeutics Inc

* Pluristem's Phase III study of PLX-PAD cells for the treatment of critical limb ischemia cleared by U.S. FDA

* Pluristem expects to begin enrolling patients in its Phase III study in both U.S. and Europe during first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below